The major shortfalls of Valeant Pharmaceuticals (VRX) are well known throughout the investment world. But according to TheStreet's Jim Cramer, there's a core group of investors that continue to believe in the company.

Will Valeant's earnings results on Tuesday encourage investors to stay long the stock?

Obviously Valeant's competitors can smell blood in the water and want to buy some of Valeant's more attractive businesses, Cramer, the co-manager of the Action Alerts PLUS portfolio, said from the floor of the New York Stock Exchange Monday.

The company's CEO recently said management is weighing price cuts on some of products, which would be "pretty devastating," Cramer reasoned. However, the hardest pill to swallow with Valeant comes in the form of debt.

Simply put, Valeant has too much of it and needs to find a way to lighten the load. If the company can find a way to lower its debt and shed some non-core assets, then the stock will higher, Cramer explained.

Analysts expect the company to earn $1.75 per share on $2.49 billion in revenue.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

5 Things We Learned About Activist Investing in 2017

5 Things We Learned About Activist Investing in 2017

Valeant Pharmaceuticals Stock Still a Dog?

Valeant Pharmaceuticals Stock Still a Dog?

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)